New drug shows promise for Hard-to-Treat blood cancers

NCT ID NCT04018248

First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 28 times

Summary

This early-phase trial tested a new drug called BR101801 in 26 adults with advanced blood cancers like lymphoma and leukemia that had not responded to other treatments. The main goals were to find a safe dose and check for side effects. The study had two parts: one to determine the right dose and another to see how well the drug worked in a specific type of lymphoma.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Asan Medical Center

    Seoul, South Korea

  • Chonnam National University Hwasun Hospital

    Hwasun, Jeollanam-do, South Korea

  • Henry Ford Hospital

    Detroit, Michigan, 48202, United States

  • Inje University Busan Paik Hospital

    Busan, South Korea

  • National Cancer Center

    Goyang-si, Gyeonggi-do, South Korea

  • Samsung Medical Center

    Seoul, South Korea

  • Seoul National University Bundang Hospital

    Seongnam-si, Gyeonggi-do, South Korea

  • Seoul national university hospital

    Seoul, South Korea

  • Severance Hospital, Yonsei University Health System

    Seoul, South Korea

Conditions

Explore the condition pages connected to this study.